Drug intelligence / Profile preview

N-(4-oxo-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-2-yl)acetamide

Development stage
Unknown
Modality
Small Molecules
01

Overview

N-(4-Oxo–5,6 ,7 ,8-tetrahydro–[1.3]-thiazolo[5.4-c]-azepin–2–yl)-acetamide is a small molecule compound with the molecular formula C9H11N3O2S and a molecular weight of approximately 225.27 g/mol.[2][3][4][5] It belongs to the class of organic compounds known as n-acetylarylamines (a type of acetamides). The compound has been referenced in chemical databases such as DrugBank (DB08776), PubChem (CID:739358), and ChemSpider (ID:646276). It is considered an experimental molecule and there are no approved therapeutic indications or marketed products containing this substance.[2][3][5] No detailed mechanism of action or biological target has been established in public sources; it is primarily used for research purposes.

Other names
N-{4-oxo-[1,3]thiazolo[5,4-c]azepin-2-yl}acetamideN-(4-Oxo–5,6,7,8-tetrahydro–[1.3]-thiazolo[5.4-c]-azepin–2–yl)-acetamideAcetamide,N-(5,6 ,7 ,8 -tetrahydro - 4 - oxo - 4 H-thiazolo [ 5 , 4 – c ] azepin – 2 – yl )-
02

Targets

CYP3A4 (Cytochrome P450 3A4)CHEK1 (Checkpoint kinase 1)

Beyond the preview

Go deeper on N-(4-oxo-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-2-yl)acetamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-(4-oxo-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-2-yl)acetamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call